Products & Services · Revenue
Other — Revenue
Eli Lilly Other — Revenue decreased by 12.2% to $187.00M in Q1 2026 compared to the prior quarter.
Analysis
StatementSegment
CategoryGrowth
SignalContext dependent
VolatilityModerate
First reportedQ1 2025
Last reportedQ1 2026
Rolls up toTotal Revenue
How to read this metric
An increase may indicate successful monetization of legacy assets or non-core business activities, while a decrease often reflects the natural decline of mature products or a strategic shift toward core therapeutic areas.
Detailed definition
This metric represents the total net sales generated from products or services that do not fall into the company's prima...
Peer comparison
Peers often report this as 'Other Revenue' or 'All Other' segments, which typically show declining trends as companies divest non-core assets to focus on high-growth therapeutic areas.
Metric ID:
lly_segment_other_revenueHistorical Data
2 periods
| Q1 '25 | Q1 '26 | |
|---|---|---|
| Value | $213.00M | $187.00M |
| QoQ Change | — | -12.2% |
| YoY Change | — | -12.2% |
Range$187.00M – $213.00M
Avg YoY Growth-12.2%
Median YoY Growth-12.2%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Eli Lilly's other — revenue?
- Eli Lilly (LLY) reported other — revenue of $187.00M in Q1 2026.
- What does other — revenue mean?
- Total revenue generated from products or services that are not part of the company's main reporting segments.